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Pharmacokinetic studies and anticancer activity of 
curcumin-loaded nanostructured lipid carriers
In order to investigate the potential of nanostructured lipid 
carriers for efficient and targeted delivery of curcumin, the 
pharmacokinetic parameters of curcumin-loaded nano-
structured lipid carriers (Cur-NLC) were evaluated in rats 
after a single intraperitoneal dose of Cur-NLC. In addition, 
the anticancer activity of Cur-NLC against human lung ad-
enocarcinoma A549 cells was verified by a cellular uptake 
study, and a cytotoxicity and apoptosis assay. Bioavailability 
of Cur-NLC was better than that of native curcumin (p > 0.01), 
as seen from the area under the plasma concentration-time 
curve (AUC), maximum plasma concentration (Cmax), mean 
residence time (MRT) and total plasma clearance (CLz/F). 
Cur-NLC has a more obvious lung-targeting property in 
comparison with native curcumin. Cur-NLC showed high-
er anticancer activity in vitro against A549 cells than native 
curcumin (IC50 value of 5.66 vs. 9.81 mg L–1, respectively). 
Meanwhile, Cur-NLC treated A549 cells showed a higher 
apoptosis rate compared to that of native curcumin. These 
results indicate that NLC is a promising system for the 
delivery of curcumin in the treatment of lung adenocarci-
noma.
Keywords: curcumin, nanostructured lipid carriers, phar-
macokinetic, anticancer effects, lung adenocarcinoma
Lung cancer is by far the most frequent cause of cancer-related deaths worldwide (1). 
The effectiveness of chemotherapeutic agents is often limited by the unavoidable toxicity 
of drug treatment. It is therefore essential to discover potential agents with more efficient 
therapeutic strategies and less severe side effects for the treatment of lung cancer. Phyto-
chemicals have been gaining increasing attention as chemopreventive agents to treat vari-
ous diseases, including lung cancer. Curcumin (C21H20O6), a hydrophobic polyphenol, is 
an important phytochemical compound that gives the Asian spice turmeric its light yellow 
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or for medication purposes worldwide, especially in India and other east Asian countries. 
77 % curcumin I (diferuloylmethane), 17 % curcumin II (demethoxycurcumin) and 3 % 
curcumin III (bis-demethoxycurcumin) are the three major constituents of curcumin. 
Studies have indicated that curcumin has cancer preventive activity, either alone or in 
combination with other anticancer agents. Curcumin’s widespread availability, safety, low 
cost and multiple cancer fighting functions make it a promising drug for the treatment of 
numerous cancers, including lung, cervical, breast, hepatic, pancreatic and colon cancer 
(2–5). The most attractive and vital reason for the therapeutic use of curcumin is its supe-
rior safety profile. It has been demonstrated that curcumin has very low toxicity, even at 
very high doses (6). Nevertheless, native curcumin cannot reach the therapeutic target in 
a therapeutic concentration because of its low bioavailability. Therefore, curcumin should 
be formulated in such a way that it can overcome these critical issues. In the current study, 
nanoformulations of curcumin have been designed with the aim of improving curcumin 
physicochemical and pharmacokinetic properties (7).
The solid lipid nanoparticle (SLN) has received much attention as an efficient and 
nontoxic carrier delivery system. SLN has numerous advantages, which include targeted 
drug delivery, increased stability and solubility of the incorporated drug (8). Nanostruc-
tured lipid carrier (NLC) is the second-generation of SLN. As a novel drug delivery system, 
NLC can improve release properties, reduce drug expulsion during storage and increase 
the chemical stability of incorporated drugs (9, 10). Furthermore, NLC can be formulated 
for various administration routes, including oral, pulmonary, intravenous, and percutane-
ous (11). In our early study, Cur-NLC was prepared successfully by the emulsion-evapora-
tion and low temperature-solidification technique. Water solubility of Cur-NLC was better 
than that of native curcumin. In addition, drug entrapment efficiency and loading capacity 
of Cur-NLC were both adequate (12).
Intraperitoneal (i.p.) administration of curcumin-loaded NLC has not been investi-
gated to date. Several studies have shown that curcumin nanoparticles have anticancer 
properties (13). Recent studies have reported that curcumin has shown potential therapeu-
tic value in lung cancer. The chemopreventive effect of curcumin was largely based on its 
effectiveness to inhibit cell proliferation and induce cancer cell apoptosis (14). The purpose 
of this study is to investigate the pharmacokinetics of curcumin after i.p. administration 
of Cur-NLC in rats. In addition, we evaluated the in vitro anticancer activity of Cur-NLC 
against the human lung adenocarcinoma cell line A549.
eXPeRIMeNTAL
Materials
Curcumin (purity > 98 %) was purchased from Sinopharm Chemical Reagent Co., Ltd., 
China. Monostearin (MS) was obtained from hunan erkang Pharmaceutical Co., Ltd., 
China. Tween-80 was purchased from Sonopharm Chemical Reagent Co., Ltd., China. 
Lecithin and octyl decyl acid triglycerate were provided by Anhui Fengyuan Pharmaceu-
tical Co., Ltd., China. Poloxamer 188 (Pluronic F68) was purchased from BASF (germany). 
Methanol (Merck, germany) was of hPLC grade. RPMI-1640 medium, defined fetal bovine 
serum (FBS), and 1 % penicillin-streptomycin were obtained from gibco (USA), while di-
methyl sulfoxide (DMSO), sodium carboxymethylcellulose (CMC-Na), 2,5-diphenyltetra-
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zolium bromide (MTT) were purchased from Sigma-Aldrich (USA). Annexin V-fluoresce-
in isothiocyanate/propidium iodide (Annexin V-FITC/PI) was purchased from NanJing 
Keygen Biotech Co., Ltd., China. The human lung adenocarcinoma cell line A549 was 
obtained from the Institute of Biochemistry and Cell Biology, Institute for Biological Sci-
ences, Chinese Academy of Science (Shanghai, China). Water used was doubly distilled 
and all other chemicals were of analytical grade.
Preparation of Cur-NLC
Cur-SLN was formulated using the fast emulsification and low temperature-solidifi-
cation technique, which was described in detail in our previous study (12). Based on the 
Cur-SLN formulation procedure, Cur-NLC was formulated by adding additional liquid 
lipid (octyl decyl acid triglycerate) into Cur-SLN. This is the only difference between Cur-
NLC and Cur-SLN, while their other materials are the same. In brief, the lipid phase and 
the lipophilic surfactant were dissolved in a modest amount of organic solvent and then 
heated. After adding curcumin, the hot lipid phase was added into the water solution of 
hydrophilic surfactant, heated and stirred at 10000 rpm for 2 h to obtain a pre-emulsion. 
The resulting hot o/w nanoemulsion was dumped into ice cold distilled water using an 
electric stirrer (DF-1 electric Stirred, Jintan, China) and stirred for 2 h. Cur-NLC was 
formed by lipid recrystallization. The solid lipid, liquid lipid and the surfactants were 
optimized using a single factor analysis and orthogonal test (15). The optimal formula and 
technique: the ratios of drug to lipid, liquid lipid to total lipids, lecithin to total lipids, 
surfactant to water phase and Pluronic F68 to Tween-80 were 1:20, 1:10, 1:50, 3:100, and 1:1, 
respectively. Organic solvent consisted of ethanol and acetone (1:4, V/V). The ratio of na-
noemulsion to ice cold distilled water was 1:3 (V/V). The physicochemical properties in-
cluding particles size, polydispersity index (PI) and zeta potential were determined by 
photon correlation spectroscopy with a Zetasizer (Nano ZS90, Malvern, UK) at 25 °C, after 
appropriate dilution with ultrapure water. encapsulation efficiency (ee) and drug loading 
capacity (LC) of Cur-NLC were assessed indirectly by hPLC analysis. The particles size, 
polydispersity index (PI), zeta potential, ee and DL capacity of Cur-NLC were 99.99 nm, 
0.158, −19.9 mV, 97.86 %, and 4.35 %, respectively. empty NLC were formulated following 
the same procedure as for Cur-NLC without adding curcumin.
Pharmacokinetic studies
Animals and dosing. – healthy SPF Sprague-Dawley male rats (230 ± 20 g) were supplied 
by the experimental Animal Center of Anhui Medical University (hefei, China). Rats were 
allowed to eat a standard diet and drink ad libitum. They adapted to the experimental condi-
tions of 20 ± 2 °C, humidity 60 ± 5 % with a 12-hour light/dark cycle. All protocols involving 
experimental animals were approved by the Institutional Animal Care and Use Committee 
for experimental Animal Center, Anhui Medical University, China. The study was ap-
proved by the animal-related ethics regulations of Anhui Medical University, China.
After 1 week of acclimation with free access to regular rodent food and water, all rats 
were randomly and equally divided into two groups for Cur-NLC and native curcumin 
i.p. administration, respectively. One group of rats (group 1, n = 6) received a single dose 
of 40 mg kg–1 native curcumin suspension (diluted in 0.5 % CMC-Na) by i.p. injection, while 
the other group of rats (group 2, n = 6) received the same dose of curcumin in Cur-NLC. 
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After administration, serial blood samples (0.3 mL) were collected into heparinized poly-
ethylene tubes at determined time points (5, 10, 15, 30, 45, 60, 90, 120, 240 and 360 min). All 
blood samples were then centrifuged for 15 min at 3,000 rpm and 4 °C to obtain the plasma. 
Following i.p. administration for 360 min, tissues of interest (heart, liver, spleen, lung, 
kidney, brain, stomach and small intestine) were collected immediately, lightly rinsed with 
normal saline and dried with tissue paper. All plasma samples and tissues were frozen at 
−80 °C until further analysis.
Plasma and tissue sample analysis. – The concentration of delivered curcumin was deter-
mined by hPLC analysis. A 0.2 mL plasma sample was extracted and homogenized with 
300 μL of methanol (to enhance curcumin extraction), and was vortex-mixed for 4 min. The 
resulting solution was centrifuged at 3000 rpm for 15 min. The supernatant was collected into 
another clean test tube and evaporated under a stream of nitrogen at 45 °C. The residue was 
then redissolved using 500 μL mobile phase and was filtered through a 0.22 μm filter mem-
brane. 20 μL of filtrate was injected into the hPLC system to determine curcumin in plasma 
samples. Plasma concentration can be calculated with the aid of the drug concentration-peak 
areas standard curve. The plasma concentration-time data were analyzed and the pharmaco-
kinetic parameters, including AUC, MRT, Cmax, peak time (Tmax) and CLz/F, were estimated.
Tissue (30–50 mg) samples were weighed and homogenized using a glass tissue ho-
mogenizer after addition of 1 mL of physiologic saline. The process of tissue homogenates 
was similar to that of plasma samples and analyzed by hPLC.
Serum and tissue samples were all prepared using a Shimadzu LC-15C hPLC system 
(Shimadzu, Japan) with a variable wavelength UV detector and LC-Solution Lite Chinese 
chromatography data system (Agilent Technologies, China).
Curcumin III, used as internal standard, was dissolved in methanol (10 μg mL–1, 10 
μL). Detection conditions were set as follows: Kromasil C18 column (5 μm, 4.6 mm × 150 
mm) at 25 °C. The mobile phase of methanol and water (52:48, V/V) was used for chromato-
graphic separation at a flow rate of 1.0 mL min–1. Curcumin content in each sample was 
quantified at 242 nm. The detection limit was 0.03 mg kg–1 for each tissue. Analytical method 
for measuring curcumin levels in tissue homogenates (heart, liver, spleen, lung, kidney, 
brain, stomach and small intestine) was as follows. The limit of quantification in tissue for 
curcumin measurement was 0.01 μg mL–1 and the standard curves ranging from 0.01–50 
μg mL–1 demonstrated good linearity (R2 ≥ 0.998). Interday and intraday precisions were 
3.3–4.7 % and 2.7–4.1 %, respectively. The recovery of curcumin in tissue homogenates 
ranged from 90 to 109 %.
Cellular uptake. – Curcumin and Cur-NLC can emit green-yellow fluorescence natu-
rally under visible light. In this study, A549 cells were seeded in a 12-well plate at a con-
centration of 3.0 × 105 cells/well (37 °C, 5 % CO2) to monitor the cellular uptake of Cur-NLC. 
The cells were cultured in RPMI-1640 medium containing 10 % (V/V) FBS and 1 % (V/V) 
penicillin-streptomycin at 37 °C and 5 % CO2. After culturing for 24 hours, 30 mg L
–1 Cur-
NLC and native curcumin were added to the attached cells, respectively. Native curcumin 
was dissolved with DMSO for its poor water solubility (the final concentration of DMSO 
in the media was ≤ 0.1 %). After incubation for 2 and 4 hours in 37 °C, 5 % CO2, the culture 
medium of each well was removed. Treated cells were carefully washed three times with 
1× PBS. Cells of all groups were observed and photographed under a fluorescent micro-
scope (Olympus IX70, Japan) at 488 nm.
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In vitro anti-tumor assay
MTT assay. – On the day before the experiment, A549 cells were seeded in a 96-well 
plate (200 μL/well) at a density of 4 × 104 cells/well. After 24 hours, a series of determined 
concentrations of native curcumin DMSO solution, empty NLC nanoparticles and Cur-
NLC were added to cells for 48 hours. DMSO concentration in the medium was lower than 
0.1 % in order to avoid toxicity to the cells. After 48 hours of incubation, the culture me-
dium from each well was removed and the cells were washed twice with 1× PBS. Cells 
were then exposed to MTT (5 mg mL–1 in PBS) for 4 hours at 37 °C, 5 % CO2. The medium 
was carefully removed from each well, and 150 μL of DMSO was added to dissolve the 
MTT formazan crystals for 10 min. The amount of formazan was quantified at 490 nm us-
ing an enzyme-linked immunosorbent assay reader (BioTek elx×800 microplate reader, 
USA) and the results were expressed as percentages relative to the result obtained with 
non-treated cells (cells incubated with culture medium only). All treatments were tested 
in triplicate, and the results were expressed as the mean value ± SD. Cell viability (%) was 
calculated by the following equation:
 Cell viability (%) = (optical density values for experimental 
 groups/optical density values for control group) × 100 % (1)
The half maximal inhibitory concentration (IC50) was the concentration that caused 
50 % inhibition of cell viability and was calculated by the Logit method (16).
Apoptosis analysis by flow cytometry. – Anticancer activity of native curcumin and Cur-
NLC were confirmed flow cytometrically via apoptosis assay in A549 cells. A549 cells were 
stained with Annexin V-FITC/PI apoptosis detection kit, which detects phosphatidylserine 
exposed on the outer surface of the cell membrane for fluorescence-activated cell sorting 
(FACS) analysis. In brief, A549 cells at a density of 4 × 106 cells/well were seeded in 6-well 
plates and cultured until 75–85 % confluency. Cells were treated with different concentra-
tions of Cur-NLC and native curcumin (1.25, 5 and 10 mg L–1, respectively). Cells cultured 
with complete growth culture medium only were used as controls. After 48 hours, cells 
were collected by trypsinization and washed twice with cold 1 × PBS in order to wash 
away trypsin and then centrifuged at 1000 rpm for 5 min. After removing the supernatant, 
cells were stained by adding Annexin V-FITC/PI into the binding buffer.
Statistical analysis
Stained cells were placed on ice for 15 min in the dark. Processed single cell suspen-
sions were analyzed by flow cytometry (Becton Dickinson, CA, USA). Triplicates of each 
sample were analyzed. In the early apoptosis phase, cells are annexin V+/PI−. In the ne-
crotic or late apoptosis phase, cells are annexin V+/PI+. Cells staining negative for both 
annexin V and PI are live cells.
Pharmacokinetic parameters were obtained using the DAS Version 2.0 Software (Chi-
nese Pharmacological Association, China). n denotes the sample size in each group. All 
experiments were performed in triplicate and analyzed using the one-way ANOVA test 
(SPSS, version 16.0) to determine the differences between profiles. Values were expressed 
as mean ± SD. p > 0.05 was considered statistically significant.
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In vivo pharmacokinetic study
Plasma concentration time profiles and the corresponding pharmacokinetic parame-
ters after i.p. administration of native curcumin and Cur-NLC to rats at a single curcumin 
dose of 40 mg kg–1 are, respectively, presented in Fig. 1 and Table I. The pharmacokinetic 
behavior of curcumin after i.p. administration of native curcumin and Cur-NLC were fitted 
to the non-compartment model. As shown in Table I, the pharmacokinetic parameters of 
curcumin after administration of Cur-NLC are markedly different from those of native 
curcumin. The Cmax value of native curcumin was 0.49 ± 0.08 mg L–1, and the AUC0-t value 
standing for the bioavailability of native curcumin was 26.68 ± 2.98 mg h L–1. These results 
clearly illustrate the characteristic drawbacks of the i.p. administration of native curcumin, 
i.e. poor absorption resulting in low curcumin bioavailability. Conversely, it was observed 
that Cur-NLC formulation showed significantly higher curcumin Cmax (1.61-fold) and 
Fig. 1. Plasma concentration time profiles of native curcumin and Cur-NLC after i.p. administration 
of a single curcumin dose of 40 mg/kg to rats ( x ± s, n = 6).
Table I. Pharmacokinetic parameters of native curcumin and Cur-NLC af﻿ter intraperitoneal injection in rats 
( x ± s, n = 6)
Pharmacokinetic parameters Native curcumin  Cur-NLC
AUC0-t (mg h L–1) 26.68 ± 2.98 129.18 ± 15.43**
MRT0–t (min) 148.01 ± 9.55 171.86 ± 12.17**
Tmax (min) 5 ± 0.00 120 ± 30.22**
Cmax (mg L–1) 0.49 ± 0.08 0.79 ± 0.062**
CLz/F (L min–1 kg–1) 0.201 ± 0.115 0.161 ± 0.077
**p > 0.01 compared to the native curcumin group. AUC, area under the plasma concentration-time curve; MRT, 
mean residence time; Tmax, peak time; Cmax, maximum plasma concentration; CLz/F, total plasma clearance.
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AUC0-t (2.19-fold) compared to native curcumin, which suggested that Cur-NLC formula-
tion could significantly improve the relative bioavailability of native curcumin. In addi-
tion, MRT were also significantly improved (p > 0.01). Total plasma clearance (CLz/F) of 
Cur-NLC, as another important pharmacokinetic parameter, was much slower than that 
of native curcumin. Pharmacokinetic analysis showed that the relative bioavailability 
(F %) of Cur-NLC was 218.42 %.
 F (%) = AUCCur-NLC × 100 /AUCNative cucumin
evidences have suggested that i.p. administration of chemotherapeutics has obvious 
advantages in pharmacokinetics, which could elevate the local drug concentration about 
450–2900 times compared to systemic chemotherapy (17). A previous report indicated that 
nanoparticles could target the lymphatic system and act as slow-release formulations after 
i.p. administration in rats when compared to intravenous route (18). Based on our data 
from Table I, Cur-NLC formulation significantly improved the relative bioavailability of 
curcumin. It can be speculated that larger nanoparticles were taken up by the reticuloen-
dothelial system (ReS) or other tissues, which acted as a drug reservoir from which the 
drug could be slowly released, and led to markedly increased bioavailability (19). Accord-
ing to that theory, the improved pharmacokinetic parameters and relative bioavailability 
of Cur-NLC compared to native curcumin were advantageous for drug targeting to tumor 
tissue.
Tissue distribution study
AUC and the corresponding curcumin pharmacokinetic parameters in rat organs for 
the two formulations (Cur-NLC and native curcumin) are shown in Table II and Fig. 2. It can 
be calculated from Table II that AUC values of Cur-NLC in lung tissue are 1.54-fold higher 
Table II. AUC0 –t and targeting property of native curcumin and Cur-NLC af﻿ter intraperitoneal injection in 
rats (n = 6)
Tissue
AUC0-t tissue (μg g–1 h–1) Te
Ce Re
Cur-NLC Native curcumin Cur-NLC Native curcumin 
Heart        7.66 ± 0.90       22.21 ± 4.91                    0.05       0.16 0.18 0.34
Liver      93.68 ± 12.05     31.78 ± 7.97                    1.12       0.24 1.95 2.94
Spleen      30.42 ± 6.16       38.84 ± 9.21                    0.21       0.31 0.45 0.78
Lung      16.23 ± 2.09       10.02 ± 1.83                    0.10       0.07 1.08 1.61
Kidney        8.24 ± 0.99       10.06 ± 2.72                    0.05       0.07 0.36 0.81
Stomach        6.93 ± 0.85       26.46 ± 7.64                    0.04       0.19 0.06 0.26
Small 
intestine        6.34 ± 0.68       15.23 ± 3.11.                    0.04       0.10 0.13 0.41
Te – targeting efficiency, Re – relative targeting efficiency, Ce – ratio of peak plasma concentration
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Fig. 2. Curcumin tissue distribution curves after i.p. administration of native curcumin and Cur-NLC 
in a curcumin dose of 40 mg kg–1.
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than those of native curcumin. In addition, the AUC values of Cur-NLC markedly decreased 
in the heart, spleen, kidney, stomach and small intestine in comparison with native cur-
cumin. As shown in Fig. 2, the curcumin concentration and AUC0-t value in the lung both 
increase in the case of nanoformulation, while this does not occur in other organs, except 
for the liver. The concentration of curcumin was negligible in lung tissue 12 hours after the 
treatment in the native curcumin group, while curcumin was still measurable in the Cur-
NLC group. In comparison with native curcumin, the ratio of peak plasma concentration 
(Ce) and relative uptake rate equivalent (Re) of Cur-NLC were both higher than in the lung. 
In addition, targeting efficiency (Te) was also increased in the lung, which indicated that 
Cur-NLC could increase significantly the curcumin level in the lung. Thus, Cur-NLC 
showed obvious lung-targeting (Table II). The values of Re, Te and Ce seemed higher in the 
liver than in the lung when rats were treated with Cur-NLC. The possible reason was that 
liver was the principal organ for metabolizing and disposing of Cur-NLC, which led to Cur-
NLC being accumulated to a greater extent in the liver tissue than in other tissues.
 Ce = (Cmax)Cur-NLC / (Cmax)Native cucumin; Re = (AUCTissue)Cur-NLC / (AUCTissue)Native cucumin;
 Te = (AUC)target organ / (AUC)non-target organ.
Nanoparticles can promote particle recognition of the ReS by organs such as liver, lung 
and spleen by opsonization processes (20, 21). This study revealed that uptake of nanopar-
ticles from capillaries of the parietal peritoneum into the target organ might lead to Cur-
NLC distributed to lung tissue more intensively than native curcumin. high curcumin con-
centration in target tissue is vital for curcumin to have pharmacological activity.
Fig. 3. Fluorescent images of A549 cells after 2- and 4-hour treatment with Cur-NLC and native cur-
cumin. Original magnification ×400.
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In vitro cellular uptake
Fig. 3 shows a significant difference in cell uptake between Cur-NLC and native cur-
cumin. The intrinsic green-yellow fluorescence of curcumin was observed after cellular 
uptake. hours of incubation were sufficient for A549 cells to take up nanoparticles, which 
were then localized in the cytoplasm. It was obvious that A549 cells treated for 2 hours 
with native curcumin and Cur-NLC showed weaker bright yellow fluorescence than the 
cells treated for 4 hours. Control cells and empty NLC treated cells showed no fluores-
cence. Fluorescent microscopy demonstrated that the uptake efficiency of curcumin by 
A549 cells was enhanced when delivered by NLC. These results indicate that encapsula-
tion within NLC might be a useful tool for drug delivery to lung cancer cells.
A549 cells could internalize Cur-NLC more effectively than native curcumin under 
the same conditions. These results could be attributed to the small size of Cur-NLC 
nanoparticles and zeta potential, which influence the particle stability, cellular uptake, 
clearance and intracellular trafficking (22, 23). Cellular uptake of nanoparticles, as a sig-
nificant event, could be mediated through endocytosis rather than passive diffusion (24).
In vitro cytotoxicity of Cur-NLC
Using the MTT assay, cell toxicity of native curcumin and Cur-NLC against A549 cells 
was determined. The results showed that both native curcumin and Cur-NLC signifi-
cantly reduced cell viability against A549 cells in a similar dose dependent manner. As 
shown in Fig. 4, the decrease in cell viability of A549 cells was more pronounced in the case 
of Cur-NLC than in the case of native curcumin treatment. Significant difference in cell 
viability between native curcumin and Cur-NLC was measured at four different curcum-
in concentrations (2.5, 5, 10 and 20 mg L–1) after 48 hours of incubation. In vitro half maxi-
mal inhibitory concentration (IC50) was used as a quantitative measure of cytotoxicity in-
duced by a chemotherapeutic drug. IC50 values were calculated according to the obtained 
Fig. 4. In vitro cytotoxicity of native curcumin and Cur-NLC against A549 cells ( x ± s, n = 6). Data are 
the means of 3 independent experiments. *p < 0.05, **p < 0.01 compared to the same concentration of 
native curcumin.
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sigmoidal curves of A549 cells. The IC50 values of Cur-NLC and native curcumin are 
shown in Table III. It was obvious that Cur-NLC, at an equivalent dose, exhibited higher 
cytotoxicity than native curcumin. Cur-NLC was about 1.73 times more effective than na-
tive curcumin in A549 cells.
Table III. IC50 values of native curcumin and Cur-NLC in A549 cells as measured by the MTT assay
Tumor cells Native curcumin IC50 (mg L–1) Cur-NLC IC50 (mg L–1)
A549 9.81 ± 1.29 5.66 ± 0.41a
a p > 0.01 compared to native curcumin IC50
Fig. 5. effect of native curcumin and Cur-NLC in different dosages on A549 cell apoptosis. a) A549 
cells were treated with Cur-NLC and native curcumin. The apoptosis rate was the sum of the early 
and late apoptosis phases. b) Bar graph shows the effect of Cur-NLC and native curcumin on apop-
tosis of A549 cells ( x ± s, n = 3). ##p < 0.01 compared to the control group; **p < 0.01 compared to the 
empty nanoparticle treated group. c) Apoptosis rate of Cur-NLC treatment showed a more significant 
difference than that of native curcumin groups ( x ± s, n = 3). **p < 0.01 compared to the native cur-
cumin group.
a)
b)                                                                           c)
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Drug stability and the duration of intracellular drug accumulation by nanoparticle 
uptake are correlated with cytotoxicity A549 (25). It is known that the free form of the drug 
diffuses across the cell membrane when used as a solution. Therefore, further entry will 
be rapidly confined when reaching saturation inside the protoplasm, which showed weak 
cytotoxicity for a very short time (25, 26). however, Cur-NLC as a nanocarrier had abun-
dant availability inside the cell by endocytosis and encapsulated curcumin exerted sus-
tained cytotoxicity. Our cytotoxicity results confirmed that Cur-NLC, at an equivalent 
curcumin dose, exhibited stronger cytotoxicity than native curcumin. Namely, Cur-NLC 
led to higher cell death rate with lower IC50 when compared to native curcumin. The dif-
ference in the uptake profile might be the reason for stronger cytotoxicity of Cur-NLC.
Cur-NLC induce apoptosis in the A549 cell line in vitro
Consistent with the MTT assay, FACS analysis showed a dose-dependent increase in 
the proportion of apoptotic cells in Cur-NLC treatments. A549 cell apoptosis was quanti-
fied by annexin-V/PI staining (FACS analysis) after the treatment with native curcumin or 
Cur-NLC (1.25, 5 and 10 mg L–1) for 48 hours. Apoptotic cell externalize phosphatidylserine 
on the outer layer of the cell membrane to which Annexin-V binds. This flow cytometry 
method can discriminate the percentage of cells in early (Annexin-V-positive cells) and late 
apoptosis (Annexin-V and PI-positive cells) from live cells (unstained by either fluoro-
chrome) (Fig. 5). As shown in Fig. 5c, flow cytometric analysis demonstrates that Cur-NLC 
(1.25 mg L–1) treated A549 cells had a higher apoptosis rate, i.e. 19.61 % in apoptosis com-
pared to 15.67 % in native curcumin (1.25 mg L–1) treated cells, and the percentage of 
apoptotic cells increased from 15.65 % in the case of native curcumin (5 mg L–1) treatment 
to 22.37 % in the case of Cur-NLC (5 mg L–1) treatment. however, there was no statistical 
difference in the percentage of apoptotic cells between the treatments when cells were 
treated with the highest curcumin concentration (10 mg mL–1). The reason was not found. 
Further studies should be conducted in order to obtain more data on the potential of Cur-
NLC to induce apoptosis. These data revealed that both necrosis and apoptosis contrib-
uted to Cur-NLC induced death of A549 cells, and Cur-NLC treated A549 cells showed a 
higher apoptosis rate than that of native curcumin.
growing evidence revealed that apoptosis was essential for cancer therapy and rep-
resents a mechanism to counteract neoplastic development (27, 28). In recent years, accu-
mulating studies on apoptosis have demonstrated that curcumin was responsible for in-
ducing apoptosis signals in various tumor tissues, including lung cancer (27). Our study 
showed that Cur-NLC induced more apoptosis than native curcumin, which was consis-
tent with the results of the cytotoxicity assay. It is well known that increasing the concen-
tration of curcumin in the lung favors a therapeutic effect in lung cancer. In our study, we 
found that Cur-NLC could easily translocate into lung tissue and remain in this organ for 
a longer time, which would be essential for its anticancer effects in lung cancer. Based on 
these facts, NLC is an effective delivery system for curcumin in lung cancer treatment.
CONCLUSIONS
This study has revealed that NLC has markedly improved the pharmacokinetics and 
tissue distribution of curcumin after i.p. administration. The results of A549 cellular up-
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take test showed that the cellular uptake efficiency of Cur-NLC was higher than that of 
native curcumin. In vitro cytotoxicity assay and apoptosis analysis implied that Cur-NLC 
showed stronger anticancer activity than native curcumin by inhibiting proliferation and 
inducing apoptosis against A549 cells. We could draw the conclusion that these nanostruc-
tured lipid curcumin carriers possessed not only improved curcumin pharmacokinetic 
properties but also improved the anticancer activity in lung A549 cells. Therefore, Cur-
NLC could serve as a promising tool in lung cancer treatment. Further investigation is 
required to gain full understanding of its beneficial effect in preventing the progression of 
lung cancer.
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